Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician
Back
Evaluation ViewAttendees 15

Oncology

Panel Discussion: Selecting a Targeted Therapeutic based on Molecular Diagnostics

Panel Discussion: Selecting a Targeted Therapeutic based on Molecular Diagnostics

Thursday, June 15, 2023
3:00 PM – 4:00 PM ET
Location: PCC 201C
CE: 1
Capturing for On Demand

Recent advances in molecular diagnostic tests that provide insight into genetic mutations of a patient's tumor have the potential to improve clinical outcomes. However, there are multiple pharmacologic, pharmaceutical, and clinical pathology factors that may hinder the successful clinical application of this precision medicine approach. This panel is a Part II follow-up to Part I presentation on this topic; the panelist and audience will exchange ideas the importance of these when selecting a therapeutic based upon molecular diagnostic test.

Learning Objectives:

  • Describe how pharmacologic factors such as a drug’s engagement with its molecular targets, and its in vivo exposure can influence drug efficacy and safety.
  • Describe the pharmaceutical factors such as drug potency, purity, stability, and impurity characteristics, and the drug’s formulation on its efficacy and safety.
  • Describe the clinical pathology factors that need to be considered when interpreting results of molecular genetic test conducted on dogs with cancer.